Spectroscopic Studies of Delafloxacin Meglumine
Chinese Journal of Magnetic Resonance, 2021 The structure of delafloxacin meglumine was analyzed by infrared absorption (IR), ultraviolet absorption (UV), nuclear magnetic resonance (1H NMR, 13C NMR, DEPT, 1H-1H COSY, 1H-13C HSQC and 1H-13C HMBC) spectroscopy, mass spectrometry and elemental ...
Xin-yi ZHAO +4 more
doaj +2 more sources
Comparative efficacy of delafloxacin for complicated and acute bacterial skin and skin structure infections: results from a network meta-analysis [PDF]
BMC Infectious Diseases, 2021 Background Delafloxacin is a novel fluoroquinolone with broad antibacterial activity against pathogens causing acute bacterial skin and skin structure infections (ABSSSI).
Ioanna Vlachaki +6 more
doaj +2 more sources
Profile of a Novel Anionic Fluoroquinolone—Delafloxacin [PDF]
Clinical Infectious Diseases, 2019 Fluoroquinolones have been in clinical use for over 50 years with significant efficacy. However, increasing resistance and emergence of some marked adverse events have limited their usage. The most recently approved class member, delafloxacin, is the only available anionic (non-zwitterionic) fluoroquinolone.
Tulkens, Paul M +2 more
openaire +3 more sources
Evaluating the efficacy of delafloxacin and combination therapy against Staphylococcus aureus Biofilms: insights into activity in acidic environments [PDF]
Scientific ReportsStaphylococcus aureus is a major contributor to biofilm-associated infections, which complicate the treatment of chronic conditions like osteomyelitis and prosthetic infections.
Ana Paula de Andrade +4 more
doaj +2 more sources
Safety of Delafloxacin: Focus on Adverse Events of Special Interest
Open Forum Infectious Diseases, 2018 AbstractBackgroundFluoroquinolones have been widely used for a variety of Gram-positive and Gram-negative infections, and by 2002 they had become the most commonly prescribed class of antibiotics for adults in the United States. With widespread use, the class has become associated with a range of adverse events.
Thomas Lodise +3 more
openaire +3 more sources
Fluoroquinolone-Associated Psychiatric and Ocular Adverse Events: A Disproportionality Analysis Using Real-World Data From FAERS (2011-2024). [PDF]
Pharmacol Res PerspectThis pharmacovigilance study identifies a wide range of rapid‐onset neuropsychiatric and ocular adverse effects linked to fluoroquinolones (FQ). Disproportionality analysis revealed a disproportionate reporting of suicidal ideation and visual impairment following FQ treatment, emphasizing the urgent need for cautious prescribing and strengthened safety
Chau HT, Au NPB.
europepmc +2 more sources
Emerging treatment options for acute bacterial skin and skin structure infections: focus on intravenous delafloxacin [PDF]
Infection and Drug Resistance, 2018 Elda Righi, Alessia Carnelutti, Antonio Vena, Matteo Bassetti Infectious Diseases Division, Santa Maria della Misericordia University Hospital, Udine, Italy Abstract: The increase in hospitalization due to acute bacterial skin and skin ...
Righi E +3 more
doaj +2 more sources
Delafloxacin Resistance and MIC-Distribution in Ciprofloxacin-Resistant Enterobacterales: A Retrospective Evaluation of Minimum Inhibitory Concentrations [PDF]
AntibioticsObjectives: The fourth-generation fluoroquinolone delafloxacin (DFX) is propagated as a novel (oral) treatment option for infections with multidrug-resistant Gram-negatives.
Patrick Forstner +8 more
doaj +2 more sources
Some Newer Antibiotics Active Against Helicobacter pylori and Anaerobic Bacteria and the Potential Benefits of Their Wider Availability in More Countries: A Narrative Review [PDF]
AntibioticsIt is crucial to consider newer antibiotics with activity against anaerobes and Helicobacter pylori, given their healthcare importance, and the constantly growing antibiotic resistance/multidrug resistance, which complicates the therapy.
Lyudmila Boyanova +6 more
doaj +2 more sources
Evaluation of Delafloxacin against a Burkholderia pseudomallei Efflux Mutant Panel
Microbiology Spectrum, 2022 In vitro activities of delafloxacin and ciprofloxacin were evaluated against Burkholderia pseudomallei mutants expressing or lacking defined resistance-nodulation-cell division (RND) efflux pumps using CLSI methodology at pHs of 5.8 and 7.2. Delafloxacin
Sandra P. McCurdy +2 more
doaj +3 more sources